Synergistic ADPR Combinations for Enhanced Therapeutic Outcomes

The present inventive concept integrates 5′-adenosine diphosphate ribose (ADPR) compositions with distinct technologies like AI, IoT, blockchain, and novel materials to create a more powerful system for treating adenovirus-related diseases, eye disorders, cancer, and other conditions.

The original patent disclosed the use of ADPR compositions for treating various diseases. However, the original patent's limitations include the lack of personalized dosing, limited monitoring capabilities, and inadequate data tracking. The new inventive concept addresses these limitations by synergistically combining ADPR compositions with cutting-edge technologies to enhance therapeutic outcomes.

The new inventive concept comprises ADPR compositions integrated with AI modules for personalized dosing, IoT sensors for real-time monitoring, blockchain-based platforms for secure data tracking, and novel materials for targeted delivery. Claim 1 discloses a system for treating adenovirus-related diseases using AI-assisted ADPR compositions. Claim 2 describes a method for preventing eye disorders using IoT-enabled ADPR compositions. Claim 3 presents a blockchain-based platform for tracking ADPR administration. Claim 4 introduces a novel material for targeted ADPR delivery. Claim 5 outlines a system for managing cancer treatment using machine learning-assisted ADPR compositions.

The new inventive concept's novelty lies in the synergistic combination of ADPR compositions with distinct technologies, which provides a non-obvious solution to the limitations of the original patent. The inventive step is the integration of these technologies to create a more powerful system for enhanced therapeutic outcomes.

Alternative embodiments include using different AI algorithms, IoT sensors, or blockchain platforms. Variations may include integrating ADPR compositions with other technologies like robotics, nanotechnology, or gene editing.

The new inventive concept has significant commercial potential in the pharmaceutical, healthcare, and biotechnology industries. Target markets include hospitals, clinics, and research institutions focused on adenovirus-related diseases, eye disorders, cancer, and other conditions.